These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17163812)

  • 1. Initiation and progression of atherosclerosis--enzymatic or oxidative modification of low-density lipoprotein?
    Torzewski M; Lackner KJ
    Clin Chem Lab Med; 2006; 44(12):1389-94. PubMed ID: 17163812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond cholesterol: the enigma of atherosclerosis revisited.
    Bhakdi S; Lackner KJ; Han SR; Torzewski M; Husmann M
    Thromb Haemost; 2004 Apr; 91(4):639-45. PubMed ID: 15045123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection.
    Torzewski M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersusceptibility of neutrophil granulocytes towards lethal action of free fatty acids contained in enzyme-modified atherogenic low density lipoprotein.
    Lux CA; Koschinski A; Dersch K; Husmann M; Bhakdi S
    Atherosclerosis; 2009 Nov; 207(1):116-22. PubMed ID: 19423111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunopathogenesis of atherosclerosis: the Mainz hypothesis].
    Bhakdi S
    Med Monatsschr Pharm; 2006 Oct; 29(10):356-9. PubMed ID: 17058894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.
    Torzewski M; Suriyaphol P; Paprotka K; Spath L; Ochsenhirt V; Schmitt A; Han SR; Husmann M; Gerl VB; Bhakdi S; Lackner KJ
    Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2130-6. PubMed ID: 15345515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement and atherosclerosis-united to the point of no return?
    Torzewski M; Bhakdi S
    Clin Biochem; 2013 Jan; 46(1-2):20-5. PubMed ID: 23010447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An alternative hypothesis of the pathogenesis of atherosclerosis].
    Bhakdi S
    Herz; 1998 May; 23(3):163-7. PubMed ID: 9646097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis.
    Ji SR; Wu Y; Potempa LA; Qiu Q; Zhao J
    Int J Biochem Cell Biol; 2006; 38(4):648-61. PubMed ID: 16376133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity.
    Schwarz M; Spath L; Lux CA; Paprotka K; Torzewski M; Dersch K; Koch-Brandt C; Husmann M; Bhakdi S
    Thromb Haemost; 2008 Jul; 100(1):110-8. PubMed ID: 18612545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative modifications of LDL increase its binding to extracellular matrix from human aortic intima: influence of lesion development, lipoprotein lipase and calcium.
    Wang X; Greilberger J; Ratschek M; Jürgens G
    J Pathol; 2001 Sep; 195(2):244-50. PubMed ID: 11592105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatically modified LDL, atherosclerosis and beyond: paving the way to acceptance.
    Torzewski M
    Front Biosci (Landmark Ed); 2018 Jan; 23(7):1257-1271. PubMed ID: 28930598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antioxidant properties of high-density lipoproteins in atherosclerosis.
    Mackness B; Mackness M
    Panminerva Med; 2012 Jun; 54(2):83-90. PubMed ID: 22525563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of modified oxidation of low density lipoprotein in pathognesis of atherosclerosis].
    Siennicka A; Zapolska-Downar D
    Postepy Hig Med Dosw; 2003; 57(2):219-37. PubMed ID: 12866357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement protein C1q recognizes enzymatically modified low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase.
    Biro A; Ling WL; Arlaud GJ
    Biochemistry; 2010 Mar; 49(10):2167-76. PubMed ID: 20166680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative modification of lipoproteins.
    Arai H
    Subcell Biochem; 2014; 77():103-14. PubMed ID: 24374922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis.
    Matsuura E; Kobayashi K; Tabuchi M; Lopez LR
    Prog Lipid Res; 2006 Nov; 45(6):466-86. PubMed ID: 16790279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein.
    Taskinen S; Kovanen PT; Jarva H; Meri S; Pentikäinen MO
    Biochem J; 2002 Oct; 367(Pt 2):403-12. PubMed ID: 12102655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized low-density lipoprotein: a double-edged sword on atherosclerosis.
    Yu BL; Zhao SP; Huang XS
    Med Hypotheses; 2007; 69(3):553-6. PubMed ID: 17368957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.